Fennec Pharmaceuticals Inc.
TSX:FRX.TOBiotechnology
-$0.22 today
- Market cap
- $676.80M
- Beta
- 1.08
- P/E (TTM)
- -36.5
- EPS (TTM)
- -$0.24
Volume 0.00M
Average 0.00M
FRX.TO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Fennec Pharmaceuticals Inc.TSX: FRX.TO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $25.93K fell 0.3% year over year, ahead of the -1.0% change in trailing-twelve-month depreciation & amortization.
Context
- Depreciation & amortization amounted to 0.2% of revenue in FY2025, down 1.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -0.3% holds above the trailing-twelve-month pace of -1.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 103K USD
- Year-over-year change
- -87.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 103K | -87.1% |
| FY2024 | 2024-12-31 | 800K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Depreciation & Amortization vs competitors
How FRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -1.0% is the 3rd highest of 8, against a peer median of -26.6%.
- Depreciation & amortization amounts to 0.2% of revenue for FRX.TO, versus a peer median of 6.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$40.12M CAD | -6.9% | -23.0% | 12.9% | |
| LTM Mar 2026 | CA$19.76M CAD | +37.8% | — | 7.2% | |
| LTM Mar 2026 | $16.25M USD | -28.6% | -9.8% | 6.2% | |
| LTM Mar 2026 | $13.77M USD | -26.6% | -9.0% | 4.5% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $497.04K USD | -32.9% | -29.2% | 2.6% |
| LTM Mar 2026 | $263.19K USD | +45.4% | +6.5% | — | |
| LTM Mar 2026 | $101.93K USD | -1.0% | — | 0.2% | |
| LTM Apr 2026 | CA$5K CAD | -58.3% | -5.9% | — | |
| Peer median (excluding FRX.TO) | — | -26.6% | -9.4% | 6.2% | |
Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (9.74M) |
| Depreciation & Amortization | 0 | 0 | 0 | 800K | 103K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.02M | 4.22M | 5.35M | 5.06M | 7.03M |
| Change in Working Capital | (932K) | 1.1M | (6.78M) | 16.94M | (12.04M) |
| Accounts Receivables | 0 | (1.55M) | (7.27M) | (7.87M) | (12.44M) |
| Inventory | 0 | (576K) | (1.58M) | 579K | (1.28M) |
| Accounts Payables | (794K) | 1.61M | 1.39M | (537K) | 1.39M |
| Other Working Capital | (138K) | 1.61M | 683K | 24.77M | 282K |
| Other Non-Cash Items | 307K | 466K | 326K | 4.61M | (26.45K) |
| Operating Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (14.67M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 5M | 19.94M | 5M | (13M) | (19.82M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 45.01M |
| Common Stock Repurchased | 0 | (194K) | (78K) | (176K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (22K) | 797K | 1.64M | (439K) | (190.27K) |
| Financing Cash Flow | 4.98M | 20.73M | 6.64M | (13.62M) | 25.01M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (1.5M) |
| Net Change in Cash | (9.24M) | 2.67M | (10.51M) | 13.37M | 8.83M |
| Free Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (14.67M) |
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$19.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.